PMID- 35687792
OWN - NLM
STAT- MEDLINE
DCOM- 20220614
LR  - 20220630
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 146
IP  - 5
DP  - 2022 Jun 10
TI  - Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization 
      in Endometrial Serous Carcinoma.
PG  - 0
LID - 10.5858/arpa.2021-0547-OA [doi]
AB  - CONTEXT.-: Targeted anti-human epidermal growth factor receptor 2 (HER2) therapy 
      has recently become the standard for advanced-stage and recurrent HER2-positive 
      endometrial serous carcinoma (ESC) in the United States, and an endometrial 
      carcinoma-specific HER2 testing algorithm has been proposed. However, 
      comprehensive studies on the specific features of HER2 gene amplification in 
      these tumors are lacking. OBJECTIVE.-: To evaluate the characteristics of HER2 
      amplification in ESC in the context of breast and gastric HER2 fluorescence in 
      situ hybridization (FISH) guidelines. DESIGN.-: Ninety-four ESCs with available 
      HER2 immunohistochemistry (IHC) and FISH were included. HER2 IHC was scored 
      according to the proposed endometrial carcinoma-specific algorithm and FISH was 
      evaluated by using the 2018 ESC clinical trial criteria, the American Society of 
      Clinical Oncology/College of American Pathologists (ASCO/CAP) 2016 gastric 
      criteria, and ASCO/CAP 2013 and 2018 breast criteria. RESULTS.-: Most tumors 
      (90.4%; 85 of 94) had a 2+ HER2 IHC score. Polysomy of chromosome 17 was present 
      in 16% (15 of 94) and monosomy 17 was seen in 2% (2 of 94) of tumors. HER2 FISH 
      interpretation per the clinical trial criteria (HER2/CEP17 ratio >/= 2.0) showed 
      99% concordance with the current gastric and breast HER2 FISH interpretations. 
      CONCLUSIONS.-: Our results support the clinical trial criteria for HER2 FISH in 
      ESC with a modification to include HER2 IHC 2+ and HER2/CEP17 ratio less than 2.0 
      and average HER2 copy number of 6.0 or greater in the HER2-positive category. 
      Future prospective clinical investigations are necessary to assess the 
      correlation between specific HER2 FISH result categories and therapeutic 
      response.
CI  - (c) 2022 College of American Pathologists.
FAU - Buza, Natalia
AU  - Buza N
AD  - From the Department of Pathology, Yale University, New Haven, Connecticut.
FAU - Hui, Pei
AU  - Hui P
AD  - From the Department of Pathology, Yale University, New Haven, Connecticut.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Breast Neoplasms/genetics
MH  - *Cystadenocarcinoma, Serous/genetics
MH  - *Endometrial Neoplasms/genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Neoplasm Recurrence, Local
MH  - Receptor, ErbB-2/genetics/metabolism
EDAT- 2022/06/11 06:00
MHDA- 2022/06/15 06:00
CRDT- 2022/06/10 15:13
PHST- 2022/01/13 00:00 [accepted]
PHST- 2022/06/10 15:13 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/15 06:00 [medline]
AID - 482875 [pii]
AID - 10.5858/arpa.2021-0547-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2022 Jun 10;146(5):0. doi: 10.5858/arpa.2021-0547-OA.